Effect of rhG-CSF therapy on neutrophil and monocyte O2− generation
| Stimulus used for O2− generation . | Group 1 0-3 months (n = 8) . | Group 2 6-12 months (n = 8) . | ||
|---|---|---|---|---|
| Neutrophils . | Monocytes . | Neutrophils . | Monocytes . | |
| PMA, % | 48 ± 13 | 30 ± 8 | 73.5 ± 10 | 67.5 ± 12 |
| P < .01 | P < .01 | P < .03 (PR) | P < .04 (PR) | |
| fMLP, % | 32 ± 19 | 48 ± 10 | 195 ± 40 | 104 ± 12 |
| P < .01 (n = 4) | P < .01 | P < .05 (CR) | P = NS (CR) | |
| Stimulus used for O2− generation . | Group 1 0-3 months (n = 8) . | Group 2 6-12 months (n = 8) . | ||
|---|---|---|---|---|
| Neutrophils . | Monocytes . | Neutrophils . | Monocytes . | |
| PMA, % | 48 ± 13 | 30 ± 8 | 73.5 ± 10 | 67.5 ± 12 |
| P < .01 | P < .01 | P < .03 (PR) | P < .04 (PR) | |
| fMLP, % | 32 ± 19 | 48 ± 10 | 195 ± 40 | 104 ± 12 |
| P < .01 (n = 4) | P < .01 | P < .05 (CR) | P = NS (CR) | |
We measured O2− generation stimulated by either PMA or fMLP in neutrophils and monocytes obtained from controls and GSD type 1b patients. Patient O2−generation is expressed as the percentage of control O2− generation (mean ± SEM). Patients in group 1 were tested within 3 months of starting cytokine therapy, and patients in group 2 were tested after 6-12 months of therapy. TheP value is the difference between the mean activity for patient's cells and control cells, and P < .05 indicates significant difference. PR indicates that O2− generation is improved to more than 50% of control, and CR indicates that O2−generation is equivalent to or better than control. NS indicates not significant.